Arcutis Biotherapeutics, Inc.
ZORYVE
plaque psoriasis
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ZORYVE for plaque psoriasis is expected Date TBD.
Primary source
· SEC 8-K
verified 16h ago
“The Company launched ZORYVE cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5 years old following Food and Drug Administration (FDA) approval in early October 2025.”